{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:19:24Z","timestamp":1770743964545,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Serologic responses of COVID-19 vaccine are impaired in patients with B-cell lymphoma, especially those who had recently been treated with anti-CD20 monoclonal antibodies. However, it is still unclear whether those patients develop an immune response following vaccination. We investigated the efficacy of vaccination against SARS-CoV-2 in 171 patients with B-cell non-Hodgkin lymphoma (B-NHL) who received two doses of an mRNA-based COVID-19 vaccine and we compared the efficacy of vaccination to that in 166 healthy controls. Antibody titers were measured 3\u00a0months after administration of the second vaccine dose. Patients with B-NHL showed a significantly lower seroconversion rate and a lower median antibody titer than those in healthy controls. The antibody titers showed correlations with the period from the last anti-CD20 antibody treatment to vaccination, the period from the last bendamustine treatment to vaccination and serum IgM level. The serologic response rates and median antibody titers were significantly different between diffuse large B-cell lymphoma (DLBCL) patients in whom anti-CD20 antibody treatment was completed within 9\u00a0months before vaccination and follicular lymphoma (FL) patients in whom anti-CD20 antibody treatment was completed within 15\u00a0months before vaccination. Moreover, the serologic response rates and median antibody titers were significantly different among FL patients in whom bendamustine treatment was completed within 33\u00a0months before vaccination. We demonstrated that B-NHL patients who were recently treated with anti-CD20 antibodies and bendamustine had a diminished humoral response to COVID-19 vaccination. UMIN 000,045,267.<\/jats:p>","DOI":"10.1007\/s00277-023-05204-7","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:02:31Z","timestamp":1681257751000},"page":"1421-1431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8817-7107","authenticated-orcid":false,"given":"Takashi","family":"Ishio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihori","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koh","family":"Izumiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruna","family":"Muraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirei","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"issue":"7","key":"5204_CR1","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/2159-8290.CD-20-0516","volume":"10","author":"V Mehta","year":"2020","unstructured":"Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A (2020) Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov 10(7):935\u2013941. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0516","journal-title":"Cancer Discov"},{"issue":"10","key":"5204_CR2","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S1470-2045(20)30442-3","volume":"21","author":"LYW Lee","year":"2020","unstructured":"Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, Booth S, Campton NA, Cheng VWT, Collins G, Curley HM, Earwaker P, Fittall MW, Gennatas S, Goel A, Hartley S, Hughes DJ, Kerr D, Lee AJX, Lee RJ, Lee SM, McKenzie H, Middleton CP, Murugaesu N, Newsom-Davis T, Olsson-Brown AC, Palles C, Powles T, Protheroe EA, Purshouse K, Sharma-Oates A, Sivakumar S, Smith AJ, Topping O, Turnbull CD, Varnai C, Briggs ADM, Middleton G, Kerr R, Team UKCCMP (2020) COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 21(10):1309\u20131316. https:\/\/doi.org\/10.1016\/S1470-2045(20)30442-3","journal-title":"Lancet Oncol"},{"issue":"25","key":"5204_CR3","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1182\/blood.2020008824","volume":"136","author":"A Vijenthira","year":"2020","unstructured":"Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, Martin-Moro F, Razanamahery J, Riches JC, Zwicker J, Patell R, Vekemans MC, Scarfo L, Chatzikonstantinou T, Yildiz H, Lattenist R, Mantzaris I, Wood WA, Hicks LK (2020) Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 136(25):2881\u20132892. https:\/\/doi.org\/10.1182\/blood.2020008824","journal-title":"Blood"},{"issue":"10","key":"5204_CR4","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","volume":"7","author":"F Passamonti","year":"2020","unstructured":"Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, Angelucci E, Krampera M, Cairoli R, Della Porta MG, Fracchiolla N, Ladetto M, Gambacorti Passerini C, Salvini M, Marchetti M, Lemoli R, Molteni A, Busca A, Cuneo A, Romano A, Giuliani N, Galimberti S, Corso A, Morotti A, Falini B, Billio A, Gherlinzoni F, Visani G, Tisi MC, Tafuri A, Tosi P, Lanza F, Massaia M, Turrini M, Ferrara F, Gurrieri C, Vallisa D, Martelli M, Derenzini E, Guarini A, Conconi A, Cuccaro A, Cudillo L, Russo D, Ciambelli F, Scattolin AM, Luppi M, Selleri C, Ortu La Barbera E, Ferrandina C, Di Renzo N, Olivieri A, Bocchia M, Gentile M, Marchesi F, Musto P, Federici AB, Candoni A, Venditti A, Fava C, Pinto A, Galieni P, Rigacci L, Armiento D, Pane F, Oberti M, Zappasodi P, Visco C, Franchi M, Grossi PA, Bertu L, Corrao G, Pagano L, Corradini P, Investigators I-H-C (2020) Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 7(10):e737\u2013e745. https:\/\/doi.org\/10.1016\/S2352-3026(20)30251-9","journal-title":"Lancet Haematol"},{"issue":"23","key":"5204_CR5","doi-asserted-by":"publisher","first-page":"5966","DOI":"10.1182\/bloodadvances.2020003170","volume":"4","author":"WA Wood","year":"2020","unstructured":"Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, Anderson KC, Goldberg AD, Pennell NA, Niemeyer CM, Tucker E, Hewitt K, Plovnick RM, Hicks LK (2020) Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv 4(23):5966\u20135975. https:\/\/doi.org\/10.1182\/bloodadvances.2020003170","journal-title":"Blood Adv"},{"issue":"6","key":"5204_CR6","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/s41375-020-0836-7","volume":"34","author":"W He","year":"2020","unstructured":"He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, Wu D, Liang B, Lu X, Ma Y, Li L, Wang H, Chen Z, Li Q, Gale RP (2020) COVID-19 in persons with haematological cancers. Leukemia 34(6):1637\u20131645. https:\/\/doi.org\/10.1038\/s41375-020-0836-7","journal-title":"Leukemia"},{"issue":"1","key":"5204_CR7","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1111\/bjh.16801","volume":"190","author":"F Martin-Moro","year":"2020","unstructured":"Martin-Moro F, Marquet J, Piris M, Michael BM, Saez AJ, Corona M, Jimenez C, Astibia B, Garcia I, Rodriguez E, Garcia-Hoz C, Fortun-Abete J, Herrera P, Lopez-Jimenez J (2020) Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol 190(1):e16\u2013e20. https:\/\/doi.org\/10.1111\/bjh.16801","journal-title":"Br J Haematol"},{"issue":"9","key":"5204_CR8","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1038\/s41375-020-0960-4","volume":"34","author":"J van Doesum","year":"2020","unstructured":"van Doesum J, Chinea A, Pagliaro M, Pasquini MC, van Meerten T, Bakker M, Ammatuna E (2020) Clinical characteristics and outcome of SARS-CoV-2-infected patients with 8haematological diseases: a retrospective case study in four hospitals in Italy Spain and the Netherlands. Leukemia 34(9):2536\u20132538. https:\/\/doi.org\/10.1038\/s41375-020-0960-4","journal-title":"Leukemia"},{"issue":"23","key":"5204_CR9","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1002\/cncr.33160","volume":"126","author":"C Cattaneo","year":"2020","unstructured":"Cattaneo C, Daffini R, Pagani C, Salvetti M, Mancini V, Borlenghi E, D\u2019Adda M, Oberti M, Paini A, De Ciuceis C, Barbullushi K, Cancelli V, Belotti A, Re A, Motta M, Peli A, Bianchetti N, Anastasia A, Dalceggio D, Roccaro AM, Tucci A, Cairoli R, Muiesan ML, Rossi G (2020) Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer 126(23):5069\u20135076. https:\/\/doi.org\/10.1002\/cncr.33160","journal-title":"Cancer"},{"issue":"1","key":"5204_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","volume":"13","author":"J Garcia-Suarez","year":"2020","unstructured":"Garcia-Suarez J, de la Cruz J, Cedillo A, Llamas P, Duarte R, Jimenez-Yuste V, Hernandez-Rivas JA, Gil-Manso R, Kwon M, Sanchez-Godoy P, Martinez-Barranco P, Colas-Lahuerta B, Herrera P, Benito-Parra L, Alegre A, Velasco A, Matilla A, Alaez-Uson MC, Martos-Martinez R, Martinez-Chamorro C, Susana-Quiroz K, Del Campo JF, de la Fuente A, Herraez R, Pascual A, Gomez E, Perez-Oteyza J, Ruiz E, Alonso A, Gonzalez-Medina J, Martin-Buitrago LN, Canales M, Gonzalez-Gascon I, Vicente-Ayuso MC, Valenciano S, Roa MG, Monteliu PE, Lopez-Jimenez J, Escobar CE, Ortiz-Martin J, Diez-Martin JL, Martinez-Lopez J, Madrilena A, de Hematologia YH (2020) Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol 13(1):133. https:\/\/doi.org\/10.1186\/s13045-020-00970-7","journal-title":"J Hematol Oncol"},{"issue":"2","key":"5204_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/bjh.17027","volume":"191","author":"TA Fox","year":"2020","unstructured":"Fox TA, Troy-Barnes E, Kirkwood AA, Chan WY, Day JW, Chavda SJ, Kumar EA, David K, Tomkins O, Sanchez E, Scully M, Khwaja A, Lambert J, Singer M, Roddie C, Morris EC, Yong KL, Thomson KJ, Ardeshna KM (2020) Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy. Br J Haematol 191(2):194\u2013206. https:\/\/doi.org\/10.1111\/bjh.17027","journal-title":"Br J Haematol"},{"issue":"27","key":"5204_CR12","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Tureci O, Nell H, Schaefer A, Unal S, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Jansen KU, Gruber WC, Group CCT (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 383(27):2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"issue":"5","key":"5204_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T, Group CS (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384(5):403\u2013416. https:\/\/doi.org\/10.1056\/NEJMoa2035389","journal-title":"N Engl J Med"},{"issue":"10","key":"5204_CR14","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/ajh.26284","volume":"96","author":"K Herzog Tzarfati","year":"2021","unstructured":"Herzog Tzarfati K, Gutwein O, Apel A, Rahimi-Levene N, Sadovnik M, Harel L, Benveniste-Levkovitz P, Bar Chaim A, Koren-Michowitz M (2021) BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Am J Hematol 96(10):1195\u20131203. https:\/\/doi.org\/10.1002\/ajh.26284","journal-title":"Am J Hematol"},{"issue":"8","key":"5204_CR15","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","volume":"39","author":"LM Greenberger","year":"2021","unstructured":"Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL (2021) Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell 39(8):1031\u20131033. https:\/\/doi.org\/10.1016\/j.ccell.2021.07.012","journal-title":"Cancer Cell"},{"key":"5204_CR16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280163","author":"N Gagelmann","year":"2021","unstructured":"Gagelmann N, Passamonti F, Wolschke C, Massoud R, Niederwieser C, Adjalle R, Mora B, Ayuk F, Kroger N (2021) Antibody response after vaccination against SARS-CoV-2 in adults with haematological malignancies: a systematic review and meta-analysis. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2021.280163","journal-title":"Haematologica"},{"issue":"6","key":"5204_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/2643-3230.BCD-21-0139","volume":"2","author":"DJ Chung","year":"2021","unstructured":"Chung DJ, Shah GL, Devlin SM, Ramanathan LV, Doddi S, Pessin MS, Hoover E, Marcello LT, Young JC, Boutemine SR, Serrano E, Sharan S, Momotaj S, Margetich L, Bravo CD, Papanicolaou GA, Kamboj M, Mato AR, Roeker LE, Hultcrantz M, Mailankody S, Lesokhin AM, Vardhana SA, Knorr DA (2021) Disease- and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies. Blood Cancer Discov 2(6):568\u2013576. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0139","journal-title":"Blood Cancer Discov"},{"issue":"8","key":"5204_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41408-021-00534-z","volume":"11","author":"F Malard","year":"2021","unstructured":"Malard F, Gaugler B, Gozlan J, Bouquet L, Fofana D, Siblany L, Eshagh D, Adotevi O, Laheurte C, Ricard L, Dulery R, Stocker N, van de Wyngaert Z, Genthon A, Banet A, Memoli M, Ikhlef S, Sestilli S, Vekhof A, Brissot E, Marjanovic Z, Chantran Y, Cuervo N, Ballot E, Morand-Joubert L, Mohty M (2021) Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer J 11(8):142. https:\/\/doi.org\/10.1038\/s41408-021-00534-z","journal-title":"Blood Cancer J"},{"issue":"8","key":"5204_CR19","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","volume":"8","author":"K Maneikis","year":"2021","unstructured":"Maneikis K, Sablauskas K, Ringeleviciute U, Vaitekenaite V, Cekauskiene R, Kryzauskaite L, Naumovas D, Banys V, Peceliunas V, Beinortas T, Griskevicius L (2021) Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol 8(8):e583\u2013e592. https:\/\/doi.org\/10.1016\/S2352-3026(21)00169-1","journal-title":"Lancet Haematol"},{"issue":"11","key":"5204_CR20","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1001\/jamaoncol.2021.4381","volume":"7","author":"TA Ollila","year":"2021","unstructured":"Ollila TA, Lu S, Masel R, Zayac A, Paiva K, Rogers RD, Olszewski AJ (2021) Antibody response to COVID-19 vaccination in adults with hematologic malignant disease. JAMA Oncol 7(11):1714\u20131716. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4381","journal-title":"JAMA Oncol"},{"issue":"7","key":"5204_CR21","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1182\/bloodadvances.2021006333","volume":"6","author":"JSK Teh","year":"2022","unstructured":"Teh JSK, Coussement J, Neoh ZCF, Spelman T, Lazarakis S, Slavin MA, Teh BW (2022) Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Adv 6(7):2014\u20132034. https:\/\/doi.org\/10.1182\/bloodadvances.2021006333","journal-title":"Blood Adv"},{"issue":"3","key":"5204_CR22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1182\/bloodadvances.2021006101","volume":"6","author":"M Jimenez","year":"2022","unstructured":"Jimenez M, Roldan E, Fernandez-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, Peralta-Garzon S, Pujadas G, Hernandez C, Pages C, Gironella M, Fox L, Orti G, Barba P, Pumarola T, Cabirta A, Catala E, Valentin M, Marin-Niebla A, Orfao A, Gonzalez M, Campins M, Ruiz-Camps I, Valcarcel D, Bosch F, Hernandez M, Crespo M, Esperalba J, Abrisqueta P (2022) Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv 6(3):774\u2013784. https:\/\/doi.org\/10.1182\/bloodadvances.2021006101","journal-title":"Blood Adv"},{"key":"5204_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.exphem.2021.12.396","volume":"107","author":"A Tvito","year":"2022","unstructured":"Tvito A, Ronson A, Ghosheh R, Kharit M, Ashkenazi J, Magen S, Broide E, Benayoun E, Rowe JM, Ofran Y, Ganzel C (2022) Anti-CD20 monoclonal antibodies inhibit seropositive response to COVID-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment. Exp Hematol 107:20\u201323. https:\/\/doi.org\/10.1016\/j.exphem.2021.12.396","journal-title":"Exp Hematol"},{"issue":"8","key":"5204_CR24","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S2352-3026(21)00199-X","volume":"8","author":"SH Lim","year":"2021","unstructured":"Lim SH, Campbell N, Johnson M, Joseph-Pietras D, Collins GP, O\u2019Callaghan A, Fox CP, Ahearne M, Johnson PWM, Goldblatt D, Davies AJ (2021) Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. Lancet Haematol 8(8):e542\u2013e544. https:\/\/doi.org\/10.1016\/S2352-3026(21)00199-X","journal-title":"Lancet Haematol"},{"issue":"3","key":"5204_CR25","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3324\/haematol.2021.279216","volume":"107","author":"R Gurion","year":"2022","unstructured":"Gurion R, Rozovski U, Itchaki G, Gafter-Gvili A, Leibovitch C, Raanani P, Ben-Zvi H, Szwarcwort M, Taylor-Abigadol M, Dann EJ, Horesh N, Inbar T, Tzoran I, Lavi N, Fineman R, Ringelstein-Harlev S, Horowitz NA (2022) Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies. Haematologica 107(3):715\u2013720. https:\/\/doi.org\/10.3324\/haematol.2021.279216","journal-title":"Haematologica"},{"issue":"16","key":"5204_CR26","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1182\/bloodadvances.2021005094","volume":"5","author":"C Perry","year":"2021","unstructured":"Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, Tabib Y, Cohen YC, Benyamini N, Beyar-Katz O, Neaman M, Vitkon R, Keren-Khadmy N, Levin M, Herishanu Y, Avivi I (2021) Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv 5(16):3053\u20133061. https:\/\/doi.org\/10.1182\/bloodadvances.2021005094","journal-title":"Blood Adv"},{"issue":"9","key":"5204_CR27","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood.2021012443","volume":"138","author":"P Ghione","year":"2021","unstructured":"Ghione P, Gu JJ, Attwood K, Torka P, Goel S, Sundaram S, Mavis C, Johnson M, Thomas R, McWhite K, Darrall A, DeMarco J, Kostrewa J, Mohr A, Rivas L, Neiders M, Suresh L, Segal BH, Griffiths EA, Ramsperger V, Shen L, Hernandez-Ilizaliturri FJ (2021) Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies. Blood 138(9):811\u2013814. https:\/\/doi.org\/10.1182\/blood.2021012443","journal-title":"Blood"},{"issue":"11","key":"5204_CR28","doi-asserted-by":"publisher","first-page":"E410","DOI":"10.1002\/ajh.26322","volume":"96","author":"EM Jurgens","year":"2021","unstructured":"Jurgens EM, Ketas TJ, Zhao Z, Joseph Satlin M, Small CB, Sukhu A, Francomano E, Klasse PJ, Garcia A, Nguyenduy E, Bhavsar E, Formenti S, Furman R, Moore JP, Leonard JP, Martin P (2021) Serologic response to mRNA COVID-19 vaccination in lymphoma patients. Am J Hematol 96(11):E410\u2013E413. https:\/\/doi.org\/10.1002\/ajh.26322","journal-title":"Am J Hematol"},{"issue":"3","key":"5204_CR29","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/bjh.17877","volume":"196","author":"V Marasco","year":"2022","unstructured":"Marasco V, Carniti C, Guidetti A, Farina L, Magni M, Miceli R, Calabretta L, Verderio P, Ljevar S, Serpenti F, Morelli D, Apolone G, Ippolito G, Agrati C, Corradini P (2022) T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. Br J Haematol 196(3):548\u2013558. https:\/\/doi.org\/10.1111\/bjh.17877","journal-title":"Br J Haematol"},{"issue":"11","key":"5204_CR30","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1182\/bloodadvances.2021006302","volume":"6","author":"A Okamoto","year":"2022","unstructured":"Okamoto A, Fujigaki H, Iriyama C, Goto N, Yamamoto H, Mihara K, Inaguma Y, Miura Y, Furukawa K, Yamamoto Y, Akatsuka Y, Kasahara S, Miyao K, Tokuda M, Sato S, Mizutani Y, Osawa M, Hattori K, Iba S, Kajiya R, Okamoto M, Saito K, Tomita A (2022) CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma. Blood Adv 6(11):3230\u20133233. https:\/\/doi.org\/10.1182\/bloodadvances.2021006302","journal-title":"Blood Adv"},{"issue":"6","key":"5204_CR31","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/bjh.18138","volume":"197","author":"A Mori","year":"2022","unstructured":"Mori A, Onozawa M, Tsukamoto S, Ishio T, Yokoyama E, Izumiyama K, Saito M, Muraki H, Morioka M, Teshima T, Kondo T (2022) Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies. Br J Haematol 197(6):691\u2013696. https:\/\/doi.org\/10.1111\/bjh.18138","journal-title":"Br J Haematol"},{"issue":"27","key":"5204_CR32","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance AL, Lymphoma G, Eastern Cooperative Oncology G, European Mantle Cell Lymphoma C, Italian Lymphoma F, European Organisation for R, Treatment of Cancer\/Dutch Hemato-Oncology G, Grupo Espanol de Medula O, German High-Grade Lymphoma Study G, German Hodgkin\u2019s Study G, Japanese Lymphorra Study G, Lymphoma Study A, Group NCT, Nordic Lymphoma Study G, Southwest Oncology G, United Kingdom National Cancer Research I (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"2","key":"5204_CR33","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/bjh.17608","volume":"195","author":"I Avivi","year":"2021","unstructured":"Avivi I, Balaban R, Shragai T, Sheffer G, Morales M, Aharon A, Lowenton-Spier N, Trestman S, Perry C, Benyamini N, Mittelman M, Tabib Y, Bar Lev T, Zavaro M, Herishanu Y, Luttwak E, Cohen YC (2021) Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. Br J Haematol 195(2):186\u2013193. https:\/\/doi.org\/10.1111\/bjh.17608","journal-title":"Br J Haematol"},{"issue":"12","key":"5204_CR34","doi-asserted-by":"publisher","first-page":"1861e1861","DOI":"10.1016\/j.cmi.2021.07.042","volume":"27","author":"T Kageyama","year":"2021","unstructured":"Kageyama T, Ikeda K, Tanaka S, Taniguchi T, Igari H, Onouchi Y, Kaneda A, Matsushita K, Hanaoka H, Nakada TA, Ohtori S, Yoshino I, Matsubara H, Nakayama T, Yokote K, Nakajima H (2021) Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan. Clin Microbiol Infect 27(12):1861e1861-1861e1865. https:\/\/doi.org\/10.1016\/j.cmi.2021.07.042","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"5204_CR35","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/bjh.17743","volume":"195","author":"M Benda","year":"2021","unstructured":"Benda M, Mutschlechner B, Ulmer H, Grabher C, Severgnini L, Volgger A, Reimann P, Lang T, Atzl M, Huynh M, Gasser K, Petrausch U, Fraunberger P, Hartmann B, Winder T (2021) Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients. Br J Haematol 195(4):523\u2013531. https:\/\/doi.org\/10.1111\/bjh.17743","journal-title":"Br J Haematol"},{"issue":"3","key":"5204_CR36","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"5204_CR37","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"QX Long","year":"2020","unstructured":"Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, Liao P, Qiu JF, Lin Y, Cai XF, Wang DQ, Hu Y, Ren JH, Tang N, Xu YY, Yu LH, Mo Z, Gong F, Zhang XL, Tian WG, Hu L, Zhang XX, Xiang JL, Du HX, Liu HW, Lang CH, Luo XH, Wu SB, Cui XP, Zhou Z, Zhu MM, Wang J, Xue CJ, Li XF, Wang L, Li ZJ, Wang K, Niu CC, Yang QJ, Tang XJ, Zhang Y, Liu XM, Li JJ, Zhang DC, Zhang F, Liu P, Yuan J, Li Q, Hu JL, Chen J, Huang AL (2020) Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 26(6):845\u2013848. https:\/\/doi.org\/10.1038\/s41591-020-0897-1","journal-title":"Nat Med"},{"issue":"6","key":"5204_CR38","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1023\/a:1008389119525","volume":"10","author":"LD Piro","year":"1999","unstructured":"Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V (1999) Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol 10(6):655\u2013661. https:\/\/doi.org\/10.1023\/a:1008389119525","journal-title":"Ann Oncol"},{"issue":"10","key":"5204_CR39","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Foa R, Maurer J, O\u2019Brien S, Valente N, Wenger M, Maloney DG (2017) Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther 34(10):2232\u20132273. https:\/\/doi.org\/10.1007\/s12325-017-0612-x","journal-title":"Adv Ther"},{"issue":"1","key":"5204_CR40","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1182\/blood.2021013445","volume":"139","author":"N Liebers","year":"2022","unstructured":"Liebers N, Speer C, Benning L, Bruch PM, Kraemer I, Meissner J, Schnitzler P, Krausslich HG, Dreger P, Mueller-Tidow C, Poschke I, Dietrich S (2022) Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients. Blood 139(1):142\u2013147. https:\/\/doi.org\/10.1182\/blood.2021013445","journal-title":"Blood"},{"issue":"7","key":"5204_CR41","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, Marrama D, de Silva AM, Frazier A, Carlin AF, Greenbaum JA, Peters B, Krammer F, Smith DM, Crotty S, Sette A (2020) Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181(7):1489-1501 e1415. https:\/\/doi.org\/10.1016\/j.cell.2020.05.015","journal-title":"Cell"},{"issue":"6","key":"5204_CR42","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.immuni.2020.11.009","volume":"53","author":"K Lederer","year":"2020","unstructured":"Lederer K, Castano D, Gomez Atria D, Oguin TH 3rd, Wang S, Manzoni TB, Muramatsu H, Hogan MJ, Amanat F, Cherubin P, Lundgreen KA, Tam YK, Fan SHY, Eisenlohr LC, Maillard I, Weissman D, Bates P, Krammer F, Sempowski GD, Pardi N, Locci M (2020) SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation. Immunity 53(6):1281-1295e1285. https:\/\/doi.org\/10.1016\/j.immuni.2020.11.009","journal-title":"Immunity"},{"issue":"9","key":"5204_CR43","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.immuni.2021.08.001","volume":"54","author":"MM Painter","year":"2021","unstructured":"Painter MM, Mathew D, Goel RR, Apostolidis SA, Pattekar A, Kuthuru O, Baxter AE, Herati RS, Oldridge DA, Gouma S, Hicks P, Dysinger S, Lundgreen KA, Kuri-Cervantes L, Adamski S, Hicks A, Korte S, Giles JR, Weirick ME, McAllister CM, Dougherty J, Long S, D\u2019Andrea K, Hamilton JT, Betts MR, Bates P, Hensley SE, Grifoni A, Weiskopf D, Sette A, Greenplate AR, Wherry EJ (2021) Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity 54(9):2133-2142e2133. https:\/\/doi.org\/10.1016\/j.immuni.2021.08.001","journal-title":"Immunity"},{"issue":"8","key":"5204_CR44","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ccell.2021.07.016","volume":"39","author":"S Ehmsen","year":"2021","unstructured":"Ehmsen S, Asmussen A, Jeppesen SS, Nilsson AC, Osterlev S, Vestergaard H, Justesen US, Johansen IS, Frederiksen H, Ditzel HJ (2021) Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell 39(8):1034\u20131036. https:\/\/doi.org\/10.1016\/j.ccell.2021.07.016","journal-title":"Cancer Cell"},{"issue":"23","key":"5204_CR45","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","volume":"36","author":"W Hiddemann","year":"2018","unstructured":"Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Durig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE (2018) Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol 36(23):2395\u20132404. https:\/\/doi.org\/10.1200\/JCO.2017.76.8960","journal-title":"J Clin Oncol"},{"key":"5204_CR46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ijid.2022.04.058","volume":"121","author":"K Kamegai","year":"2022","unstructured":"Kamegai K, Iwamoto N, Togano T, Maeda K, Takamatsu Y, Miyazato Y, Ishikane M, Mizokami M, Sugiyama M, Iida S, Miyamoto S, Suzuki T, Ohmagari N (2022) A fatal breakthrough COVID-19 case following bendamustine-rituximab therapy. Int J Infect Dis 121:85\u201388. https:\/\/doi.org\/10.1016\/j.ijid.2022.04.058","journal-title":"Int J Infect Dis"},{"issue":"6","key":"5204_CR47","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jiac.2022.01.014","volume":"28","author":"T Arai","year":"2022","unstructured":"Arai T, Mukai S, Kazama R, Ogawa Y, Nishida K, Hatanaka K, Gohma I (2022) Persistent viral shedding of severe acute respiratory syndrome coronavirus 2 after treatment with bendamustine and rituximab: a case report. J Infect Chemother 28(6):810\u2013813. https:\/\/doi.org\/10.1016\/j.jiac.2022.01.014","journal-title":"J Infect Chemother"},{"key":"5204_CR48","doi-asserted-by":"publisher","unstructured":"Levi G, Rocchetti C, Magri R, Uccelli S, Bottone D, Quadri F, Novali M, Santin AD, Bezzi M (2021) Hyperimmune plasma infusion in an immunocompromised COVID-19 patient previously treated for follicular lymphoma. Monaldi Arch Chest Dis 91(4). https:\/\/doi.org\/10.4081\/monaldi.2021.1867","DOI":"10.4081\/monaldi.2021.1867"},{"key":"5204_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3113","author":"GM Assanto","year":"2022","unstructured":"Assanto GM, Di Rocco A, Malfona F, Capriata M, Del Giudice I, Petrucci L, Girardi P, D\u2019Elia GM, Martelli M, Gentile G, Micozzi A, Pulsoni A (2022) Impact of anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19: a retrospective study. Hematol Oncol. https:\/\/doi.org\/10.1002\/hon.3113","journal-title":"Hematol Oncol"},{"key":"5204_CR50","doi-asserted-by":"publisher","first-page":"100549","DOI":"10.1016\/j.eclinm.2020.100549","volume":"27","author":"S Lamure","year":"2020","unstructured":"Lamure S, Dulery R, Di Blasi R, Chauchet A, Laureana C, Deau-Fischer B, Drenou B, Soussain C, Rossi C, Noel N, Choquet S, Bologna S, Joly B, Kohn M, Malak S, Fouquet G, Daguindau E, Bernard S, Thieblemont C, Cartron G, Lacombe K, Besson C (2020) Determinants of outcome in COVID-19 hospitalized patients with lymphoma: a retrospective multicentric cohort study. EClinicalMedicine 27:100549. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100549","journal-title":"EClinicalMedicine"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05204-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05204-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05204-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T10:17:54Z","timestamp":1683886674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05204-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["5204"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05204-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"11 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}